326 related articles for article (PubMed ID: 19277465)
1. Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany.
De Cock E; Krueger WA; Sorensen S; Baker T; Hardewig J; Duttagupta S; Müller E; Piecyk A; Reisinger E; Resch A
Infection; 2009 Apr; 37(2):123-32. PubMed ID: 19277465
[TBL] [Abstract][Full Text] [Related]
2. Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Patel DA; Shorr AF; Chastre J; Niederman M; Simor A; Stephens JM; Charbonneau C; Gao X; Nathwani D
Crit Care; 2014 Jul; 18(4):R157. PubMed ID: 25053453
[TBL] [Abstract][Full Text] [Related]
3. Health economic evaluation of patients treated for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: secondary analysis of a multicenter randomized clinical trial of vancomycin and linezolid.
Niederman MS; Chastre J; Solem CT; Wan Y; Gao X; Myers DE; Haider S; Li JZ; Stephens JM
Clin Ther; 2014 Sep; 36(9):1233-1243.e1. PubMed ID: 25066668
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant staphylococcus aureus.
Machado AR; Arns Cda C; Follador W; Guerra A
Braz J Infect Dis; 2005 Jun; 9(3):191-200. PubMed ID: 16224625
[TBL] [Abstract][Full Text] [Related]
5. Linezolid Versus Vancomycin in the Empiric Treatment of Nosocomial Pneumonia: A Cost-Utility Analysis Incorporating Results from the ZEPHyR Trial.
Collins CD; Schwemm AK
Value Health; 2015 Jul; 18(5):614-21. PubMed ID: 26297089
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany.
Schürmann D; Sorensen SV; De Cock E; Duttagupta S; Resch A
Eur J Health Econ; 2009 Feb; 10(1):65-79. PubMed ID: 18437437
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Estes L; Orenstein R
Clin Ther; 2007 Feb; 29(2):381-3; author reply 383-4. PubMed ID: 17472831
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Lyles A
Clin Ther; 2007 Feb; 29(2):384. PubMed ID: 17472833
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Daniel Mullins C; Kuznik A; Shaya FT; Obeidat NA; Levine AR; Liu LZ; Wong W
Clin Ther; 2006 Aug; 28(8):1184-1198. PubMed ID: 16982296
[TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy for methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
Segarra-Newnham M; Church TJ
Ann Pharmacother; 2012 Dec; 46(12):1678-87. PubMed ID: 23232021
[TBL] [Abstract][Full Text] [Related]
11. Nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus treated with linezolid or vancomycin: A secondary economic analysis of resource use from a Spanish perspective.
Rello J; Nieto M; Solé-Violán J; Wan Y; Gao X; Solem CT; De Salas-Cansado M; Mesa F; Charbonneau C; Chastre J
Med Intensiva; 2016 Nov; 40(8):474-482. PubMed ID: 27061776
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis.
Bounthavong M; Zargarzadeh A; Hsu DI; Vanness DJ
Value Health; 2011; 14(5):631-9. PubMed ID: 21839399
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Estes L; Orenstem R
Clin Ther; 2007 Apr; 29(4):759-60; author reply 760-1. PubMed ID: 17617300
[No Abstract] [Full Text] [Related]
14. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
Wunderink RG; Rello J; Cammarata SK; Croos-Dabrera RV; Kollef MH
Chest; 2003 Nov; 124(5):1789-97. PubMed ID: 14605050
[TBL] [Abstract][Full Text] [Related]
15. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients.
McCollum M; Sorensen SV; Liu LZ
Clin Ther; 2007 Mar; 29(3):469-77. PubMed ID: 17577468
[TBL] [Abstract][Full Text] [Related]
16. European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid.
Chastre J; Blasi F; Masterton RG; Rello J; Torres A; Welte T
Clin Microbiol Infect; 2014 Apr; 20 Suppl 4():19-36. PubMed ID: 24580739
[TBL] [Abstract][Full Text] [Related]
17. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
McKinnon PS; Sorensen SV; Liu LZ; Itani KM
Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
[TBL] [Abstract][Full Text] [Related]
18. Estimating the cost-effectiveness of linezolid for the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Taiwan.
Lin PC; Wang BC; Kim R; Magyar A; Lai CC; Yang YW; Huang YC
J Microbiol Immunol Infect; 2016 Feb; 49(1):46-51. PubMed ID: 26454421
[TBL] [Abstract][Full Text] [Related]
19. Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Puzniak LA; Morrow LE; Huang DB; Barreto JN
Clin Ther; 2013 Oct; 35(10):1557-70. PubMed ID: 24011955
[TBL] [Abstract][Full Text] [Related]
20. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin.
Shorr AF; Susla GM; Kollef MH
Crit Care Med; 2004 Jan; 32(1):137-43. PubMed ID: 14707572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]